Do you see patients with cirrhosis in your clinic?
And do you ever have questions?
🤔 When should I refer for a TIPS?
🤔 What is the best way to monitor response to diuretics?
🤔 Is there anything I can do to change the natural course of the disease?
🧵
liverwellness.sites.uiowa.ed…
Hace dos años dejé el servicio de digestivo de Valdecilla; pero hoy mi hospital, lidera el Ranking BIC Hospitales 2026 en alta complejidad.
Los rankings cambian. El «espíritu Valdecilla» permanece: asistencia, docencia, investigación y, sobre todo, personas. Orgullo de hospital.
📑"Cribado del carcinoma hepatocelular: una guía práctica basada en la evidencia actual".
Un trabajo de @lau_mqz, Laura Carrión, Lorena Hidalgo, @aconthe, y @anamatillapena.
🔎Lo leemos en nuestra revista 'Gastro&Hepato' de julio: elsevier.es/es-revista-gastr…
It’s finally here‼️
🎉 Baveno VIII has arrived — just in time for some good summer reading ☀️📖
Time to dive into the latest consensus on portal hypertension from @BavenoCoop
Enjoy! 😉
🔗 journal-of-hepatology.eu/art…
The main bottleneck is now diagnosis and implementation. Our review proposes an integrated HBV/HCV/HDV/HIV pathway based on single-sample reflex testing, rapid linkage to care and longitudinal surveillance. reviral.esmdpi.com/1999-4915/18/8/861/…#ViralHepatitis#STI
La genética en MASLD empieza a definir subtipos biológicos, mejorar la estratificación pronóstica y abrir la puerta a tratamientos dirigidos por genotipo. De la susceptibilidad a la hepatología de precisión.
mdpi.com/1424-8247/19/8/1145#MASLD#MASH#Genetics#PrecisionMedicine
Hepatic Venous Pressure Gradient, Noninvasive Tests, and Prognosis Across the Subtypes of Advanced Steatotic Liver Disease - Clinical Gastroenterology and Hepatology cghjournal.org/article/S1542…
🚨@BavenoCoop VIII consensus document
#PortalHypertension#Cirrhosis#PSVD
2⃣7⃣2⃣ recommendations for clinical practice
1⃣5⃣3⃣ research priority topics
🎓thx to Baveno VIII faculty & all supporters
🧨soon in @JHepatology - 🍿stay tuned !!
Two-thirds of MASLD patients who qualify for a statin don't get one — mostly over a hepatotoxicity fear with no current evidential basis.
New review: why the liver may do more with statins than merely tolerate them.
@IDIVALdecilla@sepdigestiva
🔗 doi.org/10.3389/fphar.2026.1…
Original Article
Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis
Anton et al.
#LiverXtinyurl.com/3sp6bxxe